RNA Targeting Small Molecule Drug Discovery Market Trends, Drivers, and Regional Analysis 2025–2029

Uncover key drivers, emerging technologies, and competitive movements shaping the rna targeting small molecule drug discovery market from 2025–2034 with trusted insights from The Business Research Company

How Is The RNA Targeting Small Molecule Drug Discovery Market Size Expected To Expand Over 2029-2034?

The RNA targeting small molecule drug discovery market has experienced rapid expansion in recent years. This market is projected to expand from $1.76 billion in 2024 to $2.13 billion in 2025, achieving a compound annual growth rate (CAGR) of 20.8%. Historically, the market’s growth has been fueled by an increased understanding of disease genetics, genomic and proteomic discoveries, drug resistance challenges, investment in biotechnology and pharmaceutical research, and the rise of RNA therapeutics.

The RNA targeting small molecule drug discovery market is poised for significant expansion in the foreseeable future. It is projected to achieve a valuation of $4.85 billion by 2029, growing at a robust compound annual growth rate (CAGR) of 22.9%. This anticipated growth during the forecast period stems from factors such as the broadening of RNA epigenetics research, advancements in RNA-seq and functional genomics, the incorporation of artificial intelligence (AI), patient-focused strategies, and exosome-delivered therapeutics. Significant trends anticipated in this period encompass the development of RNA editing technologies, progress in CRISPR technology, various technological breakthroughs, enhancements in RNA biology understanding, and the application of RNA targeting specifically for neurodegenerative conditions.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12480&type=smp

Which Market Factors Are Fueling The RNA Targeting Small Molecule Drug Discovery Industry Growth?

The growing occurrence of cancer, genetic disorders, and viral infections is anticipated to boost the RNA-targeted small-molecule drug discovery market in the coming years. Cancer is characterized by uncontrolled cell growth within the body, while viral infections are caused by minute viruses that can only replicate inside the cells of living organisms. RNA targeting-based drug discovery offers a treatment approach for cancer, genetic disorders, and viral infections, as these conditions are linked to genes and malfunctioning genetic material, which can be addressed using therapies developed through RNA targeting methods. For example, a report from the World Health Organization (WHO), a Switzerland-based intergovernmental organization, published in February 2024, estimated 20 million new cancer cases and 9.7 million deaths globally in 2022. Lung cancer was the most prevalent, with 2.5 million new cases (12.4%), followed by female breast cancer (2.3 million cases, 11.6%), colorectal cancer (1.9 million cases, 9.6%), prostate cancer (1.5 million cases, 7.3%), and stomach cancer (970,000 cases, 4.9%). It is projected that new cancer cases will increase by 77% by 2050, reaching over 35 million annually. Consequently, the rising prevalence of cancer, genetic disorders, and viral infections is fueling the growth of the RNA-targeted small-molecule drug discovery market.

Which Categories Are Covered In The RNA Targeting Small Molecule Drug Discovery Market Segmentation Analysis?

The rna targeting small molecule drug discovery market covered in this report is segmented –

1) By Target RNA Type: Messenger RNA (mRNA), Non-Coding RNA (ncRNA), MicroRNA (miRNA), Long Non-Coding RNA (lncRNA)

2) By Technology: CRISPR-Cas9, RNA Aptamers, Small Interfering RNA (siRNA), Ribozymes, Other Technologies

3) By Therapeutic Area: Oncology, Neurology, Infectious Disease, Metabolic Diseases, Genetic Disorders, Other Therapeutic Areas

4) By Delivery Method: Intravenous (IV), Oral, Topical, Other Methods

5) By Application: Research Use, Therapeutic Use, Diagnostic Use, Other Applications

Subsegments:

1) By Messenger RNA (mRNA): Targeting mRNA For Protein Coding, Modulation Of mRNA Stability, mRNA Translation Inhibition

2) By Non-Coding RNA (ncRNA): Long Non-Coding RNA, Small Nuclear RNA, Small Nucleolar RNA

3) By MicroRNA (miRNA): miRNA Inhibition, miRNA Mimics, Targeting Specific miRNA Pathways

4) By Long Non-Coding RNA (lncRNA): lncRNA Modulators, Targeting Specific lncRNA Functions, Therapeutic Applications Of lncRNA

Which Market Trends Are Expected To Define The Future Of The RNA Targeting Small Molecule Drug Discovery Market?

The integration of artificial intelligence (AI) into drug discovery is emerging as a significant development within the small-molecule drug discovery market. Key players in the small molecule drug discovery market are employing AI technology to expedite drug discovery processes, thereby securing their market standing. A notable illustration is Google Cloud, the cloud computing division of the US-based technology company Google, which in May 2023 introduced its Target and Lead Identification Suite and Multiomics Suite to enhance the drug discovery workflow. The Multiomics Suite accelerates the identification and analysis of genetic data, empowering businesses to develop precision medicines, while the Target and Lead Identification Suite assists researchers in improving their understanding of amino acid functions and predicting protein structures.

Which Organizations Are At The Forefront Of The RNA Targeting Small Molecule Drug Discovery Market?

Major companies operating in the RNA targeting small molecule drug discovery market include F. Hoffmann-La Roche Ltd, Merck & Co. Inc, Bayer AG, Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Moderna Inc., Astellas Pharma Inc., Biogen Inc., Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Evotec A.G., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., Arrakis Therapeutics, Arbutus Biopharma Corporation, H3 Biomedicine Inc., Anima Biotech Inc., Ribometrix Inc., Quark Pharmaceuticals Inc., Regulus Therapeutics Inc., Skyhawk Therapeutics Inc., Accent Therapeutics Inc., Epics Therapeutics, Expansion Therapeutics

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecule-drug-discovery-global-market-report

Which Geographic Areas Are Driving Strong Demand For The RNA Targeting Small Molecule Drug Discovery Market?

North America was the largest region in the RNA-targeting small molecule drug discovery market in 2024. The regions covered in the RNA targeting small molecule drug discovery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=12480&type=smp

Browse Through More Reports Similar to the Global RNA Targeting Small Molecule Drug Discovery Market 2025, By The Business Research Company

Drug Discovery Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/drug-discovery-global-market-report

Drug Discovery Services Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/drug-discovery-services-global-market-report

Drug Discovery Informatics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/drug-discovery-informatics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795